MORF Morphic Holdings

Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference

Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, is scheduled to present a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020, at 8:00 a.m. PT.

A live webcast of the presentation will be available on the Investors section of Morphic’s website at . An archived replay will be available on the company’s website for a period of 90 days after the conference.

About Morphic Therapeutic



Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit .

Morphic Contact

Chris Erdman



617.686.1718

Media Contact

Tom Donovan, Ten Bridge Communications



857-559-3397

EN
08/01/2020

Underlying

MORFMorphic Holdings

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Morphic Holdings

 PRESS RELEASE
Free
MORF Morphic Holding...

Morphic Announces Corporate Highlights and Financial Results for the F...

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024 - Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disease in second quarter- -Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027- WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- (Na...

April 25, 2024 1 EN
 PRESS RELEASE
Free
MORF Morphic Holding...

Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

Morphic Appoints Dr. Simon Cooper as Chief Medical Officer Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory Diseases WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer. Dr. Cooper is an accomplished leader in drug development with appreciable success and a proven history across all phases of clinical developm...

March 19, 2024 1 EN
 PRESS RELEASE
Free
MORF Morphic Holding...

Morphic to Participate in March Investor Conferences

Morphic to Participate in March Investor Conferences WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation at investor conferences during the month of March. 3/6/249:10 AM ETGI/Microbiome Panel Discussion at the TD Cowen 44th Annual Health Care Conference 10:30 AM ETFireside Chat at the TD Cowen 44th Annual Health Care Conference 3/13/24Jefferies Biotech on the Bay SummitandLeerink Partners 2024 Global Biopharma Co...

March 5, 2024 1 EN
 PRESS RELEASE
Free
MORF Morphic Holding...

Morphic Announces Corporate Highlights and Financial Results for the F...

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023 -Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis (UC)- -Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC- -GARNET phase 2 trial of MORF-057 in Crohn’s disease (CD) expected to begin enrolling in the first half of 2024- -Ended 2023 with $704.3 million in cash and equivalents; cash runway into second half of 2027- WALTHAM, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ...

February 22, 2024 1 EN
 PRESS RELEASE
Free
MORF Morphic Holding...

Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conferenc...

Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference -Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave- WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., Chief Executive Officer of Morphic, has returned in full capacity from a previously announced temporary medical leave of absence and will present at the 42nd Annual J.P. Morgan Healthcare...

January 3, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch